**New Indications**

---

**panitumumab**

**Adjunctive Therapy**

No place in either first- or second-line treatment of metastatic colorectal cancer

---

- Adding **panitumumab** to standard protocols does not prolong survival but provokes additional adverse effects.

---

**New Products**

---

**panitumumab**

Solution to be diluted for IV infusion

**VECTIBIX®**

- 100 mg or 400 mg of **panitumumab** (20 mg/ml) per vial

---

**monoclonal antibody targeting EGFR**

---

**New indications:**

(….)wild-type KRAS metastatic colorectal cancer (…)

- in first-line in combination with Folfiri
- in second-line in combination with Folfiti.

[EU marketing authorisation, centralised procedure]

---

**Selected references from Prescrire’s literature search**

In response to our request for information, Amgen provided us with published data only.


4- Douillard JY et al. “Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (Folfox4) versus Folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer” J Clin Oncol 2010; 28 (31): 4706-4705.

5- Peeters M et al. “Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (Folfiri) compared with Folfiri alone as second-line treatment in patients with metastatic colorectal cancer” J Clin Oncol 2010; 28 (31): 4706-4713.

6- Amgen “Lettre aux professionnels de santé sur l’association du panitumumab (Vectibix®) avec des complications infectieuses de réactions dermatologiques sévères, engageant le pronostic vital ou d’issue fatale, dont des cas de fascite nécrosante” July 2012: 2 pages.